Proteomic Biomarker Framework to Speed Drug Development
FDA says efforts by CDER scientists to develop a systematic plasma proteomic biomarker framework can accelerate drug development by providing early mechanistic insights into therapeutic effects and enabling more informed decision-making in clinical trials through the selection of robust, biologically relevant biomarkers. An online post says that to evaluate the utility of omics technologies (defined in the post as scientific methods that study thousands of biological molecules simultaneously) for biomarker discovery in drug development and regulatory evaluation, the Center scientists assessed aptamer-based plasma proteomics as a representative high-throughput omics approach.
“This work addresses the challenge of integrating novel, data-rich biomarker strategies into drug development,” the post says. “The plasma proteomics framework developed by CDER researchers shows how proteomics methods and analytical frameworks can be designed, executed, and interpreted with scientific rigor, reproducibility, and regulatory relevance, and establishes a foundation for biomarker discovery and assessment that may be applied across a range of therapeutic areas.”
FDA says the large-scale method uses DNA sequences that bind specifically to proteins to measure thousands of proteins in plasma samples simultaneously. The method also allows researchers to capture a comprehensive analysis of how drugs affect multiple biological pathways simultaneously, it says, revealing pharmacodynamic responses and mechanistic insights that go beyond traditional single-target approaches.
FDA says biomarkers need three key qualities if they are to be useful for drug regulation: (1) they must be accurate; (2) they must clearly show how the drug affects the body; and (3) they must produce reliable results when tested repeatedly. “Plasma proteomics offers a path forward for the discovery of comprehensive biomarkers that meet these criteria, but it brings its own considerations,” the post explains. “High-dimensional protein data (datasets with thousands of measured proteins) require sophisticated analytical methods to extract meaningful biological insights. Variability between samples must be tightly controlled, and replication of findings across datasets is essential. Like other biomarker discovery methods, plasma proteomics faces challenges when sample numbers are extremely small, such as in single-patient scenarios in ultra-rare diseases, highlighting the importance of robust analytical frameworks for reliable biomarker identification.”
The post concludes that the CDER framework is a model for how large-scale, high-dimensional analytical methods (approaches for analyzing datasets with thousands of measured variables) such as proteomics can be applied in a scientifically rigorous way that builds regulatory confidence, enhances data transparency, and supports modern evidence-based evaluation of therapeutic products.